Encourage Your Patients to Participate! US-Based Clinical Trials That Are Actively Recruiting in Melanoma.
- Published in:
- Oncology Practice Management, 2025, v. 15, n. 5, p. 18
- Publication type:
- Article
Works matching IS 21644403 AND DT 2025 AND VI 15 AND IP 5
Results: 13
1
2
Precision Medicine in Oncology: Navigating a Complex Landscape.
- Published in:
- Oncology Practice Management, 2025, v. 15, n. 5, p. 16
- Publication type:
- Article
3
Studies Highlight the Role of Osimertinib in EGFR-Mutated Lung Cancer.
- Published in:
- Oncology Practice Management, 2025, v. 15, n. 5, p. 15
- Publication type:
- Article
4
First-Line Adagrasib Plus Pembrolizumab in KRAS G12C-Mutated NSCLC: Updated KRYSTAL-7 Data.
- Published in:
- Oncology Practice Management, 2025, v. 15, n. 5, p. 14
- Publication type:
- Article
5
Fulzerasib Combined With Cetuximab Has Potential As First-Line NSCLC Treatment.
- Published in:
- Oncology Practice Management, 2025, v. 15, n. 5, p. 13
- Publication type:
- Article
6
Elevated Interleukin-6 Correlated With THIO Plus Cemiplimab Response: A Possible Predictive Biomarker for NSCLC Treatment?
- Published in:
- Oncology Practice Management, 2025, v. 15, n. 5, p. 13
- Publication type:
- Article
7
FDA Highlights DPD Deficiency Discussions With Patients Prior to Capecitabine, 5FU Treatment.
- Published in:
- Oncology Practice Management, 2025, v. 15, n. 5, p. 11
- Publication type:
- Article
8
FDA Officials OK Durvalumab for Muscle-Invasive Bladder Cancer.
- Published in:
- Oncology Practice Management, 2025, v. 15, n. 5, p. 11
- Publication type:
- Article
9
FDA Expands Lutetium Lu 177 Vipivotide Tetraxetan Indication in Metastatic Castration-Resistant Prostate Cancer.
- Published in:
- Oncology Practice Management, 2025, v. 15, n. 5, p. 11
- Publication type:
- Article
10
Pembrolizumab Gets Nod for HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1).
- Published in:
- Oncology Practice Management, 2025, v. 15, n. 5, p. 10
- Publication type:
- Article
11
FDA Officials Approve Cabozantinib for Some Patients With Pancreatic and Extra-Pancreatic Neuroendocrine Tumors.
- Published in:
- Oncology Practice Management, 2025, v. 15, n. 5, p. 10
- Publication type:
- Article
12
Gaps Noted in Biomarker Testing and Targeted Therapy for Gastric Cancer.
- Published in:
- Oncology Practice Management, 2025, v. 15, n. 5, p. 8
- By:
- Publication type:
- Article
13
Achieving Revenue Cycle Management Mastery.
- Published in:
- Oncology Practice Management, 2025, v. 15, n. 5, p. 5
- Publication type:
- Article